Therapy Areas: Oncology
AVEO Oncology reports first patient dosed in front-line AML combination study of ficlatuzumab
15 January 2026 - US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzu...
GenomOncology and OHSU Knight Diagnostics Lab partner to enhance clinical trial matching for cancer patients
15 January 2026 - Precision medicine reporting solutions company GenomOncology (GO) announced on Wednesday that it has formed a strategic partnership with Oregon Health & Science University's...
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
14 January 2026 - Biotechnology company Rakuten Medical Inc announced on Wednesday that it has signed a biopharmaceutical contract manufacturing agreement with LOTTE Biologics, a South Korea-based com...
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas
13 January 2026 - Curasight A/S (CPH:CURAS), a Denmark-based clinical stage radiopharmaceutical company, on Monday reported encouraging preliminary data from the first patient dosed in the ongoing Pha...
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
13 January 2026 - Abbisko Therapeutics Co Ltd (HKEX:02256), a China-based, oncology-focused biopharmaceutical company, announced on Monday that the US Food and Drug Administration (FDA) has accepted t...
AbbVie licenses PD-1/VEGF bispecific antibody RC148 from RemeGen in multi-billion dollar oncology deal
12 January 2026 - Oncology company AbbVie (NYSE: ABBV) and biopharmaceutical company RemeGen announced on Monday that the companies have entered into an exclusive licensing agreement for the developme...